BR9306123A - Antiviral composition useful for the treatment or prevention of a human or veterinary viral infection and processes for treating or preventing a human or veterinary viral infection and diseases caused by human papilloma virus hepatitis C virus hepatitis virus varicella virus vaccinia virus or vaccinia viral constructs and cytomegalovirus - Google Patents

Antiviral composition useful for the treatment or prevention of a human or veterinary viral infection and processes for treating or preventing a human or veterinary viral infection and diseases caused by human papilloma virus hepatitis C virus hepatitis virus varicella virus vaccinia virus or vaccinia viral constructs and cytomegalovirus

Info

Publication number
BR9306123A
BR9306123A BR9306123A BR9306123A BR9306123A BR 9306123 A BR9306123 A BR 9306123A BR 9306123 A BR9306123 A BR 9306123A BR 9306123 A BR9306123 A BR 9306123A BR 9306123 A BR9306123 A BR 9306123A
Authority
BR
Brazil
Prior art keywords
virus
human
vaccinia
viral infection
hepatitis
Prior art date
Application number
BR9306123A
Other languages
Portuguese (pt)
Inventor
Herbert A Blough
Original Assignee
Us Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/032,234 external-priority patent/US5491135A/en
Application filed by Us Bioscience filed Critical Us Bioscience
Publication of BR9306123A publication Critical patent/BR9306123A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9306123A 1992-03-18 1993-03-18 Antiviral composition useful for the treatment or prevention of a human or veterinary viral infection and processes for treating or preventing a human or veterinary viral infection and diseases caused by human papilloma virus hepatitis C virus hepatitis virus varicella virus vaccinia virus or vaccinia viral constructs and cytomegalovirus BR9306123A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85345492A 1992-03-18 1992-03-18
US08/032,234 US5491135A (en) 1992-03-18 1993-03-17 Compositions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
PCT/US1993/002432 WO1993018763A1 (en) 1992-03-18 1993-03-18 Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals

Publications (1)

Publication Number Publication Date
BR9306123A true BR9306123A (en) 1997-08-26

Family

ID=26708159

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9306123A BR9306123A (en) 1992-03-18 1993-03-18 Antiviral composition useful for the treatment or prevention of a human or veterinary viral infection and processes for treating or preventing a human or veterinary viral infection and diseases caused by human papilloma virus hepatitis C virus hepatitis virus varicella virus vaccinia virus or vaccinia viral constructs and cytomegalovirus

Country Status (10)

Country Link
EP (1) EP0660710A1 (en)
JP (1) JPH07507770A (en)
CN (1) CN1080853A (en)
AU (1) AU3965993A (en)
BR (1) BR9306123A (en)
CA (1) CA2109435C (en)
IL (1) IL105090A (en)
IS (1) IS3987A (en)
MX (1) MX9301527A (en)
WO (1) WO1993018763A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440980B1 (en) * 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
ATE258919T1 (en) 1997-11-10 2004-02-15 Searle & Co USE OF ALKYLATED IMINOSUGARS TO TREAT MULTIPLE DRUG RESISTANCE
US6809083B1 (en) 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
US6545021B1 (en) 1999-02-12 2003-04-08 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
EP1173161A2 (en) 1999-02-12 2002-01-23 G.D. SEARLE & CO. Glucamine compounds for treating hepatitis virus infections
WO2001045727A2 (en) * 1999-12-20 2001-06-28 New Pharma Research Sweden Ab Stabilized veterinary compositions comprising more than one antiviral agent
DE10138912A1 (en) * 2001-08-08 2003-02-27 Medinnova Ges Med Innovationen Use of active substances for the prophylaxis and / or therapy of viral diseases as well as test system for finding such active substances
DE10343365A1 (en) * 2003-09-17 2005-04-14 Biosphings Ag Pharmaceutical Formulations of Xanthogenates and Inhibitors of Viral Nucleic Acid Replication
US8236768B2 (en) 2008-10-03 2012-08-07 3B Pharmaceuticals, Inc. Topical antiviral formulations
CN111317733B (en) * 2020-03-24 2022-07-12 中国人民解放军海军军医大学 Application of rifamycin antibiotics in preparation of drugs for resisting yellow fever virus infection
WO2021189444A1 (en) * 2020-03-24 2021-09-30 中国人民解放军海军军医大学 Use of rifamycin antibiotics in preparation of drugs against yellow fever virus infections
CN111419839A (en) * 2020-03-31 2020-07-17 远见生物科技（上海）有限公司 New application of rifamycin
US20230147364A1 (en) * 2020-04-30 2023-05-11 Kyoto University Prophylactic or therapeutic agent for rna virus-related diseases
EP4313150A1 (en) * 2021-03-26 2024-02-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Pyrimidine biosynthesis inhibitor combination for use in treating viral infections

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178306A (en) * 1978-08-10 1979-12-11 Parsons Jack L Preparation of N-(phosphonoacetyl)-L-aspartic acid

Also Published As

Publication number Publication date
IL105090A0 (en) 1994-08-26
IS3987A (en) 1993-09-19
MX9301527A (en) 1994-02-28
AU3965993A (en) 1993-10-21
WO1993018763A1 (en) 1993-09-30
CA2109435A1 (en) 1993-09-19
CN1080853A (en) 1994-01-19
IL105090A (en) 1998-08-16
EP0660710A4 (en) 1995-03-02
JPH07507770A (en) 1995-08-31
EP0660710A1 (en) 1995-07-05
CA2109435C (en) 1997-03-11

Similar Documents

Publication Publication Date Title
BR9306123A (en) Antiviral composition useful for the treatment or prevention of a human or veterinary viral infection and processes for treating or preventing a human or veterinary viral infection and diseases caused by human papilloma virus hepatitis C virus hepatitis virus varicella virus vaccinia virus or vaccinia viral constructs and cytomegalovirus
FI904445A0 (en) ANTIVIRAL FOERENINGAR.
EE9800382A (en) Antimicrobial treatment of herpes simplex virus and other infectious diseases
ITMI931522A0 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION (HBV)
DE69334141D1 (en) Swine virus, causative agent of the respiratory disease, vaccines and its viral DNA
ZM9387A1 (en) Treatment of diseases caused by viruses
GB9207479D0 (en) Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
EP0289550A4 (en) Vaccine for use in the therapeutic treatment of hsv.
EE9400068A (en) Mixtures for the treatment of hepatitis B virus (HBV) infection and diseases caused by it and the process of their preparation
NO923824D0 (en) USE OF TRINITROBENZENES OR CARCAMIC ACID IN TREATMENT OF CANCER OR VIRUS DISEASES
EP0382551A3 (en) Prevention and treatment of herpes virus infections
ITMI913493A1 (en) DEVICE FOR DISINFECTION OR IMMUNIZATION OF AREAS OF THE HUMAN BODY EXPOSED TO INFECTION, FROM GERMS, BACTERIA AND VIRUSES
ATE208198T1 (en) USE OF AMINOPURINES ANTIVIRAL AGENTS FOR THE TREATMENT AND PROPHYLAXIS OF LATENT HERPES VIRUS INFECTIONS
BR9916963A (en) Bupropion for the treatment of viral diseases
DK384387A (en) ERYTHROMYCINE DERIVATIVES FOR PREVENTION AND TREATMENT OF DISEASES Caused by Viruses
IL102815A (en) Pharmaceutical compositions for the treatment of infection caused by the human immunodeficiency virus
ZA9410381B (en) Use of Bradykinin antagonists for the preparation of medicaments for the treatment of virus diseases
ZA932271B (en) Compositions for the treatment of infection and disease caused by hepatitis B virus (HBV)
PT82258B (en) PREPARATION PROCESS OF COMPOSITIONS COMPOSING HUMAN INTERFERENCE AND NONYPHENOXYPOLYETANOL FOR THE TREATMENT OF VIRAL INFECTIONS BY HERPES SIMPLEX IN HUMANS
SE9201942D0 (en) AGENTS FOR TREATMENT OR PREVENTION OF DISEASES
OA09676A (en) Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases
LTIP170A (en) Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases
HU9200976D0 (en) Stabilized therapeutical preparative containing living virus, effective against viral and/or malign tumorous diseases and method for producing said preparative

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal